Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli et al. • 2023 • ENDO 2023
© 2024 Corcept Therapeutics, Incorporated
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • ENDO 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference
The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol
Greenstein & Hunt • 2023 • International Immunopharmacology
https://corcept.com/wp-content/uploads/2023/07/ECE2023-1.pdf
Simeoli et al. • 2023 • European Congress of Endocrinology
An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome
Badiu et al. • 2023 • European Congress of Endocrinology
https://corcept.com/wp-content/uploads/2023/05/AACE2023-2.pdf
Donegan et al. • 2023 • AACE 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • AACE 2023
Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors
Mann et al. • 2023 • AACR 2023
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators
Mallick et al • 2023 • Transl Res.